CODX Stock Jumps As Saudi CoMira Facility Signals Expansion

Co-Diagnostics Inc. stocks have been trading up by 68.72 percent amid heightened investor optimism surrounding its diagnostic technology developments

Live Update At 10:04:11 EDT: On Tuesday, May 19, 2026 Co-Diagnostics Inc. stock [NASDAQ: CODX] is trending up by 68.72%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CODX has been trading like a classic low-priced momentum name, with the chart telling a very different story than the income statement. Over the last few weeks, Co-Diagnostics Inc. bounced from the mid‑$1.50s to a recent close around $2.32, with a spike to $2.77 on 2026/05/19. That is a sizable percentage move for short-term traders.

Under the hood, the numbers remain rough. Recent quarterly revenue came in around $0.15M while CODX booked a net loss of about $9.1M. Profitability metrics are deeply negative, with heavy research and development and general expenses crushing the tiny top line. Yet the balance sheet is not falling apart. Co-Diagnostics Inc. shows roughly $8.2M in cash, low debt, and a current ratio near 3.9, which gives CODX room to keep funding operations.

More Breaking News

• MaxLinear Stock Rockets As AI Infrastructure Demand Ignites MXL Rally
• INM Stock Jumps On Heavy Volume As Traders Scan Charts
• GCTS Stock Surges As Traders Target Fresh Momentum
• MRVL Stock Climbs As Wall Street Supercharges AI Targets

For traders, this mix means CODX behaves like a speculative biotech: weak earnings now, optionality on future deals and execution. The negative margins explain why the stock has been stuck under $3, but the solid cash position and fresh Saudi expansion headlines help fuel sudden momentum bursts.

Why Traders Are Watching CODX After The Saudi Deal

CODX grabbed traders’ attention after news that its joint venture, CoMira Diagnostics, finalized a lease on a 14,400‑square‑foot facility in Sudair Industrial City, Saudi Arabia. This is not another vague press release about “discussions” or “frameworks.” Co-Diagnostics Inc. now has a bricks‑and‑mortar path to manufacture diagnostic instruments, lab testing equipment, medical consumables, and products tied to its Co‑Dx PCR platform in the region, pending regulatory and operational approvals.

That “turnkey” language matters. It tells traders the facility is closer to plug‑and‑play than a ground‑up build, which can shorten timelines once CODX clears approvals. The company is moving from PowerPoint to production planning.

Equally important is where this plant sits in the bigger picture. The CoMira facility is meant to serve both Saudi Arabia and the broader MENA region and is positioned under Saudi Vision 2030. For CODX, aligning with a national development program is more than PR. Vision 2030 pushes localization of high‑value industries, including healthcare. That can translate into friendlier regulators, potential local partnerships, and a stronger narrative around supply‑chain security.

Traders who watch small‑cap biotech names understand this playbook. CODX is trying to turn a small U.S. diagnostics platform into a regional manufacturing story. If Co-Diagnostics Inc. executes, the Saudi facility may evolve from news catalyst to real revenue engine. Until then, CODX trades mainly on headlines, chart levels, and volume spikes as the market handicaps that execution risk.

Conclusion

For active traders, CODX now sits at the crossroads of ugly current financials and potentially cleaner future growth. Co-Diagnostics Inc. is still posting steep losses, with negative returns on equity and assets and a revenue base that barely moves the needle. On paper, CODX does not screen well on traditional fundamentals.

But trading is about catalysts and timing, not textbook perfection. The CoMira facility lease in Sudair Industrial City gives CODX a tangible expansion angle tied directly to its Co‑Dx PCR platform, the MENA diagnostics market, and Saudi Vision 2030. That story helps explain why CODX ramped from the low $1s into the $2s on heavy volume, even while the income statement bleeds red ink.

Short-term, traders will focus on intraday volatility. The 5‑minute chart shows CODX swinging from the $1.90s to the $2.70s and back, with big range candles that reward disciplined entries and fast risk management. As Tim Bohen, lead trainer with StocksToTrade says, “For me, trading is more about managing risk than finding the next big mover.” That mindset applies directly to CODX, where the opportunity is in managing the wide ranges and controlling downside, not in blindly chasing headlines. Longer term, the market will want proof that Co-Diagnostics Inc. can move from lease signing to actual output and cash flow from Saudi operations.

As Tim Sykes loves to say, “the pattern is your edge, not the hype.” For CODX, that means respecting the volatility, tracking every update on CoMira’s regulatory and operational milestones, and remembering this is educational research, not a buy or sell call.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.